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Bordetella pertussis is the cause of whooping cough and responsible for 300,000 infant deaths per annum.
Current vaccines require 6 months to confer optimal immunity on infants, the population at highest risk.
Recently, an attenuated strain of B. pertussis (BPZE1) has been developed to be used as a low-cost, live,
intranasal, single-dose vaccine for newborns. Preclinical proof of concept has been established; however, it is
necessary to evaluate the safety of BPZE1, especially in immunodeficient models, prior to human clinical trials.
Here, the preclinical safety of BPZE1 was examined in well-characterized murine models. Immunocompetent
and gamma interferon (IFN-) receptor knockout mice were challenged by aerosol with either virulent B.
pertussis or BPZE1. The two strains colonized the lung at equal levels, but inflammation was associated with
carriage of only virulent bacteria. Virulent bacteria disseminated to the liver of IFN- receptor-deficient mice,
resulting in atypical pathology. In contrast, attenuated BPZE1 did not disseminate in either immunocompetent
or immunodeficient mice and did not induce atypical pathology. In neonatal challenge models, virulent B.
pertussis infection resulted in significant mortality of both immunodeficient and immunocompetent mice,
whereas no mortality was observed for any neonatal mice challenged with BPZE1. BPZE1 was shown to elicit
strong IFN- responses in mice, equivalent to those elicited by the virulent streptomycin-resistant B. pertussis
Tohama I derivative BPSM, also inducing immunoglobulin G2a, a process requiring TH1 cytokines in mice.
These data indicate that a live attenuated whooping cough vaccine candidate shows no signs of disseminating
infection in preclinical models but rather evokes an immunological profile associated with optimal protection
against disease.
Whooping cough remains a respiratory disease of consider-
able morbidity and mortality in children under 2 years of age.
Thirty to 50 million cases and approximately 300,000 deaths
are reported annually (11). This incidence is surprising consid-
ering that vaccines against whooping cough have been a con-
stituent of mass immunization programs for many years. In
fact, whooping cough is currently the fourth largest cause of
vaccine-preventable death (19).
In the first part of the 20th century, inactivated whole-cell
Bordetella pertussis vaccines were developed. Although they
were highly efficacious, their use was associated with adverse
reactogenicity, resulting in suboptimal vaccine coverage in
some countries and consequently a resurgence of disease (8).
In response to these issues, acellular pertussis vaccines (Pa)
were developed, consisting of purified and/or detoxified B.
pertussis components, such as pertussis toxin (PT), filamentous
hemagglutinin, and pertactin. Pa have an improved reactoge-
nicity profile and good efficacy (13). However, optimal immu-
nity induced by Pa requires three administrations, and conse-
quently, infants in the 0- to 6-month age group remain at risk
(20). The longevity of Pa-mediated protection is also subopti-
mal, and additional booster immunizations may be required to
eliminate a reservoir of infection in adolescents (41). Thus,
there is a need for a highly efficacious, single-dose B. pertussis
vaccine suitable for administration to neonates which evokes
long-lasting immunological memory.
Recently, a live attenuated B. pertussis (BPZE1) vaccine
candidate has been developed and shown to induce strong
protection in infant mice upon a single intranasal administra-
tion (32). Three virulence factors have been genetically tar-
geted to create BPZE1. PT has been modified to ablate its
enzymatic activity but retain immunogenicity. The gene encod-
ing dermonecrotic toxin (DNT) has been deleted, and the B.
pertussis ampG gene has been replaced with that of Escherichia
coli, thereby strongly diminishing tracheal cytotoxin (TCT)
production (33).
Murine models have played an important role in pertussis
vaccine research and control (22), and the potency of B. per-
tussis vaccines in murine models has been shown to correlate
with vaccine performance in human clinical trials (35). In ad-
vance of clinical studies, the safety of candidate vaccines needs
to be demonstrated; in particular, live attenuated organisms
need to be examined in immunodeficient models. Although B.
pertussis is strictly a respiratory pathogen, Mahon et al. have
shown that virulent B. pertussis can disseminate from the lungs
of immunodeficient mice, causing an atypical disease (27), and
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atypical disease has been observed in tumor necrosis factor
alpha (TNF-) knockout (KO) mice (44). However, reports of
atypical B. pertussis disease occurring in immunodeficient hu-
mans, such as individuals infected with human immunodefi-
ciency virus (HIV), are extremely rare, despite extensive cir-
culation of the pathogen in human populations (9).
To assess the safety of BPZE1, murine respiratory and neo-
natal challenge models were used here. Immunocompetent
and immunodeficient gamma interferon receptor (IFN-R)
KO mice were challenged with either virulent (the streptomy-
cin-resistant B. pertussis Tohama I derivative BPSM) or atten-
uated (BPZE1) B. pertussis and assessed for evidence of atyp-
ical infection or disease. Survival studies using neonatal mice
were carried out to determine the safety of BPZE1 in neo-
nates. Taken together, the findings reported here indicate that
BPZE1 is safe in neonatal and immunodeficient preclinical
models and induces strong TH1 responses in adult mice, similar
to those induced by natural infection in humans (35).
MATERIALS AND METHODS
Mice. Neonatal (2- to 7-day-old) or adult (6- to 8-week-old) 129/Sv (immuno-
competent) or IFN-R KO mice (36) were used under the guidelines of the Irish
Department of Health and procedures approved by the research ethics commit-
tee of the National University of Ireland, Maynooth.
Growth of B. pertussis. B. pertussis Tohama I derivatives BPSM (31) and
BPZE1 (32) have been described previously. BPSM and BPZE1 were grown at
37°C for 48 to 72 h on Bordet-Gengou agar supplemented with 15% defibrinated
horse blood. Colonies were then transferred to Stainer and Scholte liquid me-
dium containing streptomycin (30 g/ml). Cultures were grown to mid-log phase
and were maintained carefully to prevent phase modulation.
Aerosol infection. Respiratory infection was initiated by aerosol challenge with
BPSM and BPZE1 according to established protocols (15). Bacteria from mid-
log-phase cultures (2  1010 CFU/ml) were delivered by nebulizer over a 20-min
period to mice housed in an exposure chamber such that colonization of between
4  105 and 7  105 CFU/lung was achieved. This dose was chosen for consis-
tency with previous reports of atypical pathology in this model (27) and with
previous studies examining the effect of dose in the aerosol challenge model (4).
Control mice were challenged with a sham aerosol of 1% (wt/vol) casein solution
in sterile physiological saline.
Enumeration of viable bacteria. Lungs and livers were removed aseptically
from mice and homogenized in 1 ml of 1% (wt/vol) casein in sterile physiological
saline. One hundred microliters of serially diluted homogenate from individual
lungs was placed onto Bordet-Gengou agar plates in triplicate, and the numbers
of CFU were determined after incubation at 37°C for 72 h.
Histopathological examination. To assess pulmonary inflammation and injury,
entire mouse lungs were fixed by immersion in 10% (vol/vol) formalin, and
following paraffin embedding, 3-m longitudinal sections were cut, stained with
hematoxylin and eosin, and examined (15). Histopathological changes were
graded semiquantitatively based on the distribution, nature, and severity of the
observed tissue injury and inflammation as very mild (/), mild (), moderate
(), or severe () by three researchers without prior knowledge of the
treatment group (15).
Semiquantitative RT-PCR. The identity of the bacterial colonies was con-
firmed as being virulent, non-phase-modulated B. pertussis colonies by reverse
transcription-PCR (RT-PCR). This was also performed on liver and lung ho-
mogenates. RNA was isolated from cultures or homogenates using Tri reagent
(Invitrogen, Renfrew, United Kingdom) according to the manufacturer’s instruc-
tions. cDNA was then examined for expression of recA, vrg6, or ptxS1. Primer
pairs were as follows: recA, 5-GCATGAAGATCGGCGTGA-3 and 5-CGCA
CCGAGGAATAGAACTTG-3; ptxS1, 5-CGCGCCAATCCCAACCCCTA
C-3 and 5-GAAAGCTCCGAGGCCATGGCAG-3; vrg6, 5-TCTAGATACT
GCCACACATGA-3 and 5-GTCGACGCATAACGGCTGGTGGAAGG-3.
Cytokine recall responses to B. pertussis. Spleens were isolated from 129/Sv
mice that were sham inoculated with phosphate-buffered saline (PBS) or inoc-
ulated with B. pertussis BPSM or BPZE via aerosol. Splenocytes were isolated by
disaggregation of spleens and cultured in triplicate (5  104 CFU/ml of heat-
killed BPSM) at a concentration of 1  106 cells/ml in a total volume of 200 l.
After 72 h of incubation, culture supernatants were sampled for cytokine analysis
(43).
Cytokine and specific antibody measurement. Cytokine concentrations in cul-
ture supernatants were determined by enzyme-linked immunosorbent assay
(ELISA) using commercially available assays: IFN- and interleukin-5 (IL-5)
(R&D Systems, Abingdon, United Kingdom) were measured according to the
manufacturer’s instructions. Cytokine concentrations were calculated by com-
parison with known cytokine standards, all determinations were made in tripli-
cate, and results are presented as mean cytokine concentration (standard error
of the mean [SEM]).
Antibody end point serum titers for immunoglobulin E (IgE) and IgG sub-
classes (IgG1, -2a, -2b, and -3) were determined using an indirect ELISA as
previously described (28). End point titers were calculated by an established
method (45).
Statistical methods. All results are expressed as the mean  standard error. A
Student t test was used to determine significance between the groups. A value of
P	 0.05 was considered significant. Analyses and graphical representations were
performed using Graph-Pad Prism software (Graphpad, San Diego, CA).
RESULTS
Attenuated BPZE1 does not cause an atypical disseminated
disease in IFN-R KO mice. Atypical pathology and dissemi-
nated B. pertussis infection are very rare in humans. Neverthe-
less, virulent strains have been shown to cause atypical disease
in IFN- or IFN-R KO mice (23, 27) and to disseminate to
the liver of IFN-R KO mice (27), consistent with the fact that
IFN- is known to play an important role in protection against
B. pertussis (26). Therefore, the profile of infection by virulent
and attenuated B. pertussis strains was examined in immuno-
competent and IFN-R KO mice. BPZE1 colonized airways of
wild-type mice at levels similar to those of virulent B. pertussis
(BPSM) (Fig. 1), confirming that the combined attenuation of
PT, DNT, and TCT did not interfere with bacterial coloniza-
tion or “take” (32). Likewise, colonization of the airways of
IFN-R KO mice was not significantly different between
BPZE1 and virulent BPSM (Fig. 1), although the latter group
displayed a greater bacterial burden than did their wild-type
counterparts (Fig. 1). While attenuated BPZE1 colonized sim-
ilarly to the virulent strain (Fig. 1), the bacterial load at days 7
and 10 postchallenge was less than that observed in mice chal-
FIG. 1. Attenuated BPZE1 and virulent BPSM colonize lungs at
similar levels. 129/Sv (closed symbols) and IFN-R KO (open symbols)
mice were challenged by aerosol with either BPSM (squares) or
BPZE1 (circles) such that colonization of between 4 105 and 7 105
CFU/lung was achieved. Groups of mice were sacrificed at intervals
after challenge, and the number of viable bacteria was estimated by
performing colony counts on individual lung homogenates. Results are
presented as mean (SEM) CFU in the lungs, detected in triplicate
from three mice at each time point and for each group. SEMs are
present for all points but may be masked by the symbol at some data
points.
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lenged with virulent B. pertussis. This difference was significant
in 129/Sv mice at days 7 (P 
 0.0193) and 10 (P 
 0.0007) and
in IFN-R KO mice at day 10 (P 
 0.0092). No evidence of
persistent infection was observed in any of these mice, with all
groups clearing infection by day 28 after challenge.
Microbiological, pathological, and molecular characteriza-
tion of immunocompetent and IFN-R KO mice was carried
out after challenge with virulent BPSM or attenuated BPZE1.
In particular, the liver and spleen were examined for signs of
disseminated infection or atypical pathology. No evidence for
disseminated infection by BPZE1 in IFN-R KO mice was
found (Table 1). BPZE1 was not detected in the liver (Table 1)
or spleen or blood (data not shown) of challenged IFN-R KO
mice at any time point examined. In contrast, virulent BPSM
caused an atypical, disseminated disease in IFN-R KO mice
(Table 1), similar to that seen previously when the virulent B.
pertussis strain W28 was employed (27). This atypical presen-
tation was detectable in the liver from day 7 postinfection
onwards. Colonies retrieved from the lung and liver were con-
firmed by RT-PCR for recA, vrg6, and ptxS1 as being viable,
non-phase-modulated, virulent B. pertussis. Interestingly, viru-
lent BPSM was also detected at low levels in the liver of
wild-type mice (Table 1), a finding not seen previously with the
W28 strain (27). Taken together, these data support the use of
BPZE1 as a safe candidate vaccine in populations containing
immunocompromised hosts and suggest a role for PT, DNT, or
TCT alone or in combination in atypical presentation.
Attenuated BPZE1 does not cause atypical pathology in the
airways of immunodeficient mice. Infection with virulent B.
pertussis leads to characteristic pathology in the airways of
humans that can be modeled in part by murine respiratory
challenge (35). The possible pathological effect of pulmonary
colonization by BPZE1 or by virulent BPSM of immunocom-
petent and IFN-R KO mice was assessed. Lung pathology was
scored semiquantitatively, based on an assessment of the dis-
tribution, nature, and severity of injury and inflammation, as
described previously (16). Lesions in infected animals were
compared to those in sham-challenged controls which did not
exhibit any significant tissue changes (Fig. 2). Infection of ei-
ther immunocompetent or IFN-R KO mice with BPSM re-
sulted in the induction of typical pulmonary pathology from
day 7 onwards, with increasing degrees of pulmonary inflam-
mation characterized by multifocal intra-alveolar aggregates of
admixed intact and degenerate neutrophils and macrophages,
frequently adjacent to small bronchioles (Fig. 2A and C). In
contrast, BPZE1 did not induce an inflammatory exudate in
immunocompetent or IFN-R KO mice (Fig. 2B and D). Peri-
airway/perivascular lymphoid cuffing was noted, to various de-
grees, from day 14 onwards, in both 129/Sv (Fig. 2E and F) and
IFN-R KO (Fig. 2G and H) mice challenged with either
BPSM (Fig. 2E and G) or BPZE1 (Fig. 2F and H). Airway
pathology () was notable at day 21 in both 129/Sv and
IFN-R KO mice challenged with virulent BPSM (Fig. 2I and
K). In contrast, BPZE1-challenged mice displayed no airway
damage (/) (Fig. 2J and L), but development of bronchus-
associated lymphoid tissue was prominent, suggesting the in-
duction of specific immunity. Histological scores in BPZE1-
challenged mice were minimal (i.e., did not exceed ) in any
lung sections, in contrast to the widespread pathology recorded
for BPSM-infected mice (Table 2).
Attenuated BPZE1 mimics wild-type infection in generating
a TH1-polarized response. Immunity induced by existing acel-
lular whooping cough vaccines wanes, leading to potential res-
ervoirs for infection in adolescents who have previously re-
ceived vaccination (2, 38). Natural infection, however, induces
a strong TH1 response, which confers long-lasting immunity
(26, 34). For this reason, it is likely that closely mimicking
natural infection could result in improved efficacious vaccines
against B. pertussis. As BPZE1 is a live vaccine, delivered
directly to a mucosal surface, and mimics natural infection
(32), the nature of the immune response induced by BPZE1
was investigated. Mice were challenged with either virulent
BPSM, attenuated BPZE1, or a sham inoculation, and immune
responses were examined at day 40 postchallenge, a time point
when bacterial infection had been cleared. Sham-challenged
mice produced minimal recall responses to inactivated B. per-
tussis, as expected (Fig. 3). In contrast, BPSM challenge of
immunocompetent mice evoked high levels of IFN- and low
levels of IL-5 upon restimulation. Similarly, BPZE1 induced
high levels of IFN- and low levels of IL-5 (Fig. 3) in response
to restimulation by inactivated B. pertussis, typical of a strong
TH1-type response.
T-cell-derived cytokines have a major influence on the class
of immunoglobulin secreted from B cells (18). The presence of
IL-4 is necessary for class switching from IgM to IgG1 and IgE
(39), whereas IFN- is essential for switching to an IgG2a
response in mice (17). IFN- is known to play an important
role in protection against B. pertussis (8, 12). To further analyze
the immune response, serum samples from the same mice were
examined for B. pertussis-specific total IgG, IgG1, IgG2a, and
IgE. As expected, only baseline levels of all antibody classes
were observed in sham-challenged mice. In contrast, BPZE1
challenge induced a strong B. pertussis-specific IgG response
(1/30,000) but little IgE (	1/10). The predominant subclass of
B. pertussis-specific IgG was IgG2a (1/2,100), while IgG1 was
found at much lower concentrations (1/100) (Table 3). This is
characteristic of a TH1-influenced humoral response, closely
resembling that shown previously for natural infection (34).
Quantitatively and qualitatively similar antibody titers were
observed in BPZE1-immunized 129/Sv mice (total IgG,
1/45,000; IgG2a, 1/4,000; IgG1, 1/250). Together, these results
show that BPZE1 induces strong TH1-polarized immunity in
adult mice similar to that generated through virulent challenge
and associated with optimal immune responses in humans (2).
TABLE 1. BPZE1 fails to disseminate to the liver
Time
postchallenge
(days)
Bacterial burden for mouse strain (CFU/liver)a
Virulent B. pertussis
(BPSM)
Live attenuated
B. pertussis (BPZE1)
129/Sv IFN-R KO 129/Sv IFN-R KO
1 0 0 0 0
7 710  30 6,530  1,960 0 0
10 470  105 2,600  115 0 0
14 560  120 1,070  177 0 0
21 50  30 1,130  540 0 0
a 129/Sv and IFN-R KO mice were challenged with either BPSM or BPZE1.
Livers from four mice per group per time point were homogenized, serially
diluted, and plated in triplicate onto Bordet-Gengou agar. Results are presented
as mean CFU per liver  SEM (n 
 4).
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Attenuated BPZE1 is safe in a neonatal mouse model. Vir-
ulent B. pertussis can cause a lethal infection in neonatal mice
(41). Therefore, groups of neonatal (0- to 7-day-old) wild-type
(129/Sv) or IFN-R KO mice were challenged with BPSM or
BPZE1 or sham challenged with PBS, and survival was moni-
tored over a period of 35 days. A survival rate of 100% was
observed in the PBS control group. As with other virulent
strains (42), BPSM infection resulted in high rates of mortality
FIG. 2. Virulent B. pertussis BPSM (A, C, E, G, I, and K) induces pathology not seen with attenuated BPZE1 (B, D, F, H, J, and L) in the lungs
of 129/Sv (A, B, E, F, I, and J) or IFN-R KO (C, D, G, H, K, and L) mice, at day 10, 14, or 21 postchallenge. Periairway/perivascular lymphoid
cuffing was noted to various degrees in the lungs of 129/Sv (E and F) or IFN-R KO (G and H) mice on day 14 after infection with either BPSM
(E and G) or BPZE1 (F and H), indicative of the formation of bronchus-associated lymphoid tissue hyperplasia (b). BPZE1-challenged mice
showed reduced levels of pulmonary inflammation (PI) and inflammatory exudate (e) compared to those of mice challenged with BPSM. High
levels of pathology () are noted at day 21 postinfection in 129/Sv (I and J) and IFN-R KO (K and L) mice challenged with BPSM (I and
K), whereas no airway damage was observed (/) in BPZE1-challenged mice (J and L). Original magnification, 200 (A to D) or 100 (E to
L). Lung tissue was fixed, embedded, and stained using hematoxylin and eosin. Histology was scored using a previously described semiquantitative
system (14).
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in neonatal animals, with a 40 to 50% fatality rate in IFN-R
KO and immunocompetent mice prior to day 35 postchallenge
(Fig. 4A). In marked contrast, no mortality was seen when
immunocompetent or immunocompromised mice were chal-
lenged with BPZE1.
Since neonatal mice and humans are less immunocompetent
than adults (25), the ability of neonatal mice to restrict a
BPZE1 infection to the lung was therefore examined. Liver
samples were taken from neonatal mice at days 7 and 10
postinfection and examined for bacterial load; the time points
were chosen to reflect the maximum likelihood of detecting
atypical infection. Mice that received virulent BPSM showed
considerable signs of disseminating infection (Fig. 4B and D).
Similar levels of bacterial burden were seen in immunocom-
petent and IFN-R KO neonatal mice challenged with virulent
BPSM (Fig. 4B and D). In contrast, neonatal mice that re-
ceived attenuated BPZE1 showed no signs of disseminating
systemic infection, distress, or weight loss (Fig. 4C and E and
data not shown).
DISCUSSION
This study demonstrates the safety of a recently developed,
attenuated strain of B. pertussis, BPZE1, intended for use as a
low-cost, live, intranasal vaccine against whooping cough (32).
Previously, virulent B. pertussis has been shown to cause an
atypical disease in IFN-R KO mice (27). BPZE1 was unable
to cause an atypical disease in IFN-R KO mice. It failed to
induce the lung pathology associated with virulent B. pertussis
and, in contrast to virulent bacteria, was shown to be safe in a
neonate mouse model, opening the possibility of this new-
generation live attenuated vaccine being used in neonates.
Vaccination with BPZE1 induced strong TH1 responses, sim-
ilar to those elicited by natural infection.
Unlike Bordetella bronchiseptica, reports of atypical B. per-
tussis disease in immunodeficient humans, such as individuals
infected with HIV, are rare (21, 40). B. pertussis is known to
cause atypical pathology in certain immunodeficient mouse
strains, notably atypical disease in IFN-R KO mice, NK-
deficient mice, and mice lacking TNF- (6, 27, 44). It was
therefore important to document whether a live attenuated
vaccine candidate, BPZE1, could cause atypical pathology in
immunocompromised hosts. The IFN-R model was chosen
for this study because atypical disease is striking in this model
and the absence of IFN- is also a key aspect of atypical
disease in the NK-deficient model (4). The aerosol challenge
model was also chosen because the effects of bacterial dose,
mouse strain, and other parameters on the immune response
are well characterized (4). Virulent B. pertussis BPSM colo-
nized the livers of both mouse strains, albeit to a significantly
higher degree in IFN-R KO mice than in immunocompetent
mice. In contrast, attenuated BPZE1 failed to disseminate to
the liver of either mouse strain, despite levels of lung coloni-
zation similar to those for BPSM. These data confirm the role
of IFN- in the restriction of B. pertussis to the airways of
infected individuals and support the use of attenuated B. per-
tussis as a safe vaccine for immunodeficient individuals. How-
ever, further studies are needed to elucidate the precise nature
of the role of IFN- in B. pertussis infection, which seems
nonredundant. While challenge with virulent B. pertussis
strains of most other KO mice has only subtle influences on
pathological presentation, it will be important to examine the
FIG. 3. Priming with either virulent B. pertussis BPSM or attenu-
ated BPZE1 induced a TH1-polarized response. Cell-mediated im-
mune responses were examined from spleen cell cultures after sham
inoculation, virulent BPSM infection, or attenuated BPZE1 challenge.
IFN- (closed bars) and IL-5 (open bars) recall responses were mea-
sured in spleen cell culture supernatant after restimulation with inac-
tivated BPSM at 1  104 CFU/ml. Determinations were made from
four mice, and each was carried out in triplicate; results are expressed
as means (SEM).
TABLE 2. BPZE1 does not induce inflammatory pathology in a
murine model
Time
postchallenge
(days)
Pathology of experimental groupa
Virulent B. pertussis
(BPSM)
Live attenuated
B. pertussis (BPZE1)
129/Sv IFN-R KO 129/Sv IFN-R KO
0 (3 h) / / / 
7    /
10    
14    
21   / /
a 129/Sv and IFN-R KO mice were challenged with either BPSM or BPZE1.
Lungs were then removed at 0, 7, 10, 14, and 21 days postinfection; embedded in
paraffin; and stained using hematoxylin and eosin. Pathological changes were
then scored semiquantitatively, based on the distribution, nature, and severity of
the observed pulmonary injury and inflammation, as very mild (/), mild (),
moderate (), or severe () (n 
 3).
TABLE 3. BPZE1 induces IgG2a but not IgG1 or IgE in
challenged mice
Immunoglobulin
class/subclass
Serum end point titer for mouse groupa:
Naive BPZE1immunized
BPSM
infected
Total IgG 	1/10 1/30,000 1/35,000
IgG1 	1/10 1/100 1/200
IgG2a 	1/10 1/2,100 1/1,900
IgG2b 	1/10 1/600 1/1,000
IgG3 	1/10 1/100 1/100
IgE 	1/10 	1/10 1/10
a BALB/c mice were challenged with virulent BPSM, attenuated BPZE1, or a
sham inoculum of 1% (wt/vol) casein in PBS. At day 40 postinfection, serum
samples were taken from all groups of mice and analyzed by ELISA for B.
pertussis-specific total IgG, IgG1, IgG2a, IgG2b, IgG3, and IgE. Results are
expressed as mean end point titers; experiments were performed three times, for
triplicates in each case.
1348 SKERRY ET AL. CLIN. VACCINE IMMUNOL.
effects of immunization in other models, especially TNF- KO
mice (44) and mice lacking CD4 cells; however, we have
found no evidence of disseminated infection by BPZE1 in
SCID mice by using the related intranasal challenge model
(data not shown). In this study, the virulent BPSM strain of B.
pertussis showed some dissemination in immunocompetent
mice not seen in previous studies when the W28 strain was
used (27); it is unclear why the two virulent strains are different
in this regard, but it may reflect the extended culture history of
the W28 strain compared to that of BPSM.
In addition to the issues of disseminated infection and atyp-
ical pathology, the possibility of delayed clearance or possible
chronic infection by the live vaccine strain in immunocompro-
mised models required attention. Berkowitz et al. (5) reported
extended periods of infection accompanied by dyspnea in an
immunocompromised whooping cough patient; increased se-
FIG. 4. (A) BPZE1 does not cause lethal infection in neonatal KO mice. Neonate IFN-R KO (open symbols) or 129/Sv (closed symbols) mice
(less than 7 days) were infected with either virulent B. pertussis BPSM (squares) or BPZE1 (circles). Mice were observed over a period of 35 days,
and survival was recorded. *, note that BPZE1-challenged 129/Sv mice showed 100% survival but that the curve has been offset from 100% for
clarity in this figure. (B) BPZE1 did not disseminate to the liver of neonatal 129/Sv (wild-type) or IFN-R KO mice. Neonatal 129/Sv and IFN-R
KO mice were challenged with either virulent BPSM or attenuated strain BPZE1, mice were then sacrificed at days 7 and 10, and lungs and livers
were removed and examined for B. pertussis colonization. Dissemination was reduced in 129/Sv mice compared to IFN-R KO mice challenged
with BPSM. Results are presented as mean (SEM) CFU in the liver, detected individually from five mice from each group.
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verity and delayed clearance have also been noted both in
HIV/AIDS patients and in recently vaccinated HIV-positive
children (1, 5, 10, 12). Barbic et al. also observed an increased
bacterial load in the lungs of B. pertussis-infected IFN--de-
pleted mice (3). Although reports of persistent infection and
severe disease in immunocompromised humans are rare (9),
these findings, coupled with reports of poor IFN- expression
by infants (24), prompted an examination of the persistence of
infection and pathology in mouse models. Infection with either
bacterial strain in adult immunodeficient or immunocompe-
tent models resolved by day 28, suggesting that even individu-
als with impaired TH1 function would retain the ability to clear
the challenge. These data also confirm that attenuations in
BPZE1 do not compromise colonization, which is important to
support the establishment of strong immune responses (32).
The three genetic alterations present in BPZE1 were de-
signed to maintain colonization and immunogenicity while re-
ducing pathology. This was achieved through the genetic inac-
tivation of the highly immunogenic PT rather than its removal,
the total removal of DNT, and the reduction of secreted TCT
through E. coli ampG expression. Lung samples from mice
challenged with the attenuated strain showed only a mild cel-
lular infiltration on day 10, consistent with the induction of
specific immune responses, whereas over 21 days virulent
BPSM infection induced increasing pathology in mice, charac-
terized by immune cell infiltration, the presence of a fibrinous
exudate, and obstruction of the alveolar spaces (Fig. 2).
B. pertussis is a significant cause of infant death and is able
to cause a lethal infection in neonatal mouse models (42).
Virulent BPSM infection resulted in high mortality in both
immunocompetent 129/Sv and IFN-R KO neonatal mice. In
marked contrast, all immunocompetent and immunocompro-
mised neonatal mice survived BPZE1 challenge, showing no
signs of distress, weight loss, or atypical disease. This finding
attests to the safety of BPZE1 in mice and, in combination with
other studies (33), increases confidence in the proposed use of
BPZE1 as a neonatal vaccine.
It has been shown elsewhere that the infant immune system
has a poor capacity to generate TH1-type responses (29), and
most newborn children have TH2-type skewed immune re-
sponses (37). Current Pa vaccines have been shown to induce
TH2-type responses (14, 15, 30). TH1-dominated immune re-
sponses have been linked with optimal immunity against B.
pertussis (2, 4, 7, 34). The use of a live vaccine delivered directly
to mucosal surfaces closely imitates natural infection, and the
ability of the bacteria to persist until the initiation of adaptive
responses allows for the potential to develop strong memory
responses. In adult mice, BPZE1 mimicked wild-type infection
by eliciting a specific IFN-/IgG2a response, but little IL-5,
IgG1, or IgE. It would be unwise to attempt a precise corre-
lation of immunological memory in murine models with the
longevity of protection in humans; nevertheless, this study
demonstrates two important attributes of vaccination with
BPZE1: first, the ability of BPZE1 to produce a strong TH1-
polarized response that could potentially skew formative im-
mune responses away from atopy-associated TH2-type priming
(28), and second, the ability of vaccination to produce a re-
sponse which is similar to natural infection in both quality and
quantity (26, 35).
In view of the impact of whooping cough in early childhood
(11) despite current wide vaccination coverage, there is a need
for novel whooping cough vaccines to be included in mass
immunization programs. Previous preclinical data on protec-
tive immunogenicity (32) and the findings from this study sup-
port the use of a live attenuated B. pertussis vaccine strain,
BPZE1, as a safe candidate suitable for vaccinations of neo-
nates, even of populations that include immunodeficient sub-
jects. The data presented here indicate that BPZE1 lacks key
virulence factors that are linked to atypical pathology and
lethal infection in neonates. BPZE1 does not cause atypical
pathology in either adult or neonatal IFN-R KO mice and,
consequently, meets the preclinical criteria for a candidate
vaccine against whooping cough. It is now possible to consider
BPZE1 as a potential live human vaccine against whooping
cough.
ACKNOWLEDGMENTS
This work was supported by a grant from the European Commission
under the seventh framework, grant agreement number 201502
(CHILD-Innovac). C.M.S. is an IRCSET and John Hume scholar.
REFERENCES
1. Adamson, P. C., T. C. Wu, B. D. Meade, M. Rubin, C. R. Manclark, and P. A.
Pizzo. 1989. Pertussis in a previously immunized child with human immuno-
deficiency virus infection. J. Pediatr. 115:589–592.
2. Ausiello, C. M., R. Lande, F. Urbani, A. la Sala, P. Stefanelli, S. Salmaso, P.
Mastrantonio, and A. Cassone. 1999. Cell-mediated immune responses in
four-year-old children after primary immunization with acellular pertussis
vaccines. Infect. Immun. 67:4064–4071.
3. Barbic, J., M. Leef, D. Burns, and R. Shahin. 1997. Role of gamma inter-
feron in natural clearance of Bordetella pertussis infection. Infect. Immun.
65:4904–4908.
4. Barnard, A., B. P. Mahon, J. Watkins, K. Redhead, and K. H. Mills. 1996.
Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: vari-
ables in the in vivo priming and in vitro cytokine detection techniques affect
the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 87:372–
380.
5. Berkowitz, D. M., R. I. Bechara, and L. L. Wolfenden. 2007. An unusual
cause of cough and dyspnea in an immunocompromised patient. Chest
131:1599–1602.
6. Byrne, P., P. McGuirk. S. Todryk, and K. H. Mills. 2004. Depletion of NK
cells results in disseminating lethal infection with Bordetella pertussis associ-
ated with a reduction of antigen-specific Th1 and enhancement of Th2, but
not Tr1 cells. Eur. J. Immunol. 34:2579–2588.
7. Cahill, E. S., D. T. O’Hagan, L. Illum, A. Barnard, K. H. G. Mills, and K.
Redhead. 1995. Immune responses and protection against Bordetella pertussis
infection after intranasal immunization of mice with filamentous haemag-
glutinin in solution or incorporated in biodegradable microparticles. Vaccine
13:455–462.
8. Cherry, J. D. 1992. Pertussis: the trials and tribulations of old and new
pertussis vaccines. Vaccine 10:1033–1038.
9. Cohn, S. E., K. L. Knorr, P. H. Gilligan, M. L. Smiley, and D. J. Weber. 1993.
Pertussis is rare in human immunodeficiency virus disease. Am. Rev. Respir.
Dis. 147:411–413.
10. Colebunders, R., C. Vael, K. Blot, J. Van Meerbeeck, J. Van den Ende, and
M. Ieven. 1994. Bordetella pertussis as a cause of chronic respiratory infection
in an AIDS patient. Eur. J. Clin. Microbiol. Infect. Dis. 13:313–315.
11. Crowcroft, N. S., and R. G. Pebody. 2006. Recent developments in pertussis.
Lancet 367:1926–1936.
12. Doebbeling, B., M. L. Feilmeier, and L. A. Herwaldt. 1990. Pertussis in an
adult man infected with the human immunodeficiency virus. J. Infect. Dis.
161:1296–1298.
13. Englund, J. A., M. D. Decker, K. M. Edwards, M. E. Pichichero, M. C.
Steinhoff, and E. L. Anderson. 1994. Acellular and whole-cell pertussis vac-
cines as booster doses: a multicenter study. Pediatrics 93:37–43.
14. Ennis, D. P., J. Cassidy, and B. P. Mahon. 2005. Acellular pertussis vaccine
protects against exacerbation of allergic asthma due to Bordetella pertussis in
a murine model. Clin. Diagn. Lab. Immunol. 12:409–417.
15. Ennis, D. P., J. Cassidy, and B. P. Mahon. 2005. Whole-cell pertussis vaccine
protects against Bordetella pertussis exacerbation of allergic asthma. Immu-
nol. Lett. 97:91–100.
16. Ennis, D. P., J. Cassidy, and B. P. Mahon. 2004. Prior Bordetella pertussis
infection modulates allergen priming and the severity of airway pathology in
a murine model of allergic asthma. Clin. Exp. Allergy 34:1488–1497.
1350 SKERRY ET AL. CLIN. VACCINE IMMUNOL.
17. Finkelman, F., I. Katona, T. Mosmann, and R. Coffman. 1988. IFN-gamma
regulates the isotypes of Ig secreted during in vivo humoral immune re-
sponses. J. Immunol. 140:1022–1027.
18. Finkelman, F. D., J. Holmes, I. M. Katona, J. F. Urban, M. P. Beckmann,
L. S. Park, K. A. Schooley, R. L. Coffman, T. R. Mosmann, and W. E. Paul.
1990. Lymphokine control of in vivo immunoglobulin isotype selection.
Annu. Rev. Immunol. 8:303–333.
19. Forsyth, K. D., C.-H. Wirsing von Konig, T. Tan, J. Caro, and S. Plotkin.
2007. Prevention of pertussis: recommendations derived from the second
Global Pertussis Initiative roundtable meeting. Vaccine 25:2634–2642.
20. Grant, C. C., R. Roberts, R. Scragg, J. Stewart, D. Lennon, D. Kivell, R.
Ford, and R. Menzies. 2003. Delayed immunisation and risk of pertussis in
infants: unmatched case-control study. BMJ 326:852–853.
21. Janda, W. M., E. Santos, J. Stevens, D. Celig, L. Terrile, and P. C. Schre-
ckenberger. 1994. Unexpected isolation of Bordetella pertussis from a blood
culture. J. Clin. Microbiol. 32:2851–2853.
22. Kendrick, P. L., G. Eldering, M. K. Dixon, and J. Misner. 1947. Mouse
protection tests in the study of pertussis vaccine: a comparative series using
the intracerebral route for challenge. Am. J. Public Health Nations Health
37:803–810.
23. Khelef, N., C. M. Bachelet, B. B. Vargaftig, and N. Guiso. 1994. Character-
ization of murine lung inflammation after infection with parental Bordetella
pertussis and mutants deficient in adhesins or toxins. Infect. Immun. 62:2893–
2900.
24. Lewis, D., A. Larsen, and C. Wilson. 1986. Reduced interferon-gamma
mRNA levels in human neonates. Evidence for an intrinsic T cell deficiency
independent of other genes involved in T cell activation. J. Exp. Med.
163:1018–1023.
25. Mahon, B. P. 2001. The rational design of vaccine adjuvants for mucosal and
neonatal immunization. Curr. Med. Chem. 8:1057–1075.
26. Mahon, B. P., M. T. Brady, and K. H. G. Mills. 2000. Protection against
Bordetella pertussis in mice in the absence of detectable circulating antibody:
implications for long-term immunity in children. J. Infect. Dis. 181:2087–
2091.
27. Mahon, B. P., B. J. Sheahan, F. Griffin, G. Murphy, and K. H. G. Mills. 1997.
Atypical disease after Bordetella pertussis respiratory infection of mice with
targeted disruptions of interferon-gamma receptor or immunoglobulin 
chain genes. J. Exp. Med. 186:1843–1851.
28. Marchant, A., T. Goethebuer, M. Ota, I. Wolfe, S. Ceesay, D. De Grote, T.
Corrah, S. Bennett, J. Wheeler, K. Huygen, P. Aaby, W. McAdam, and M.
Newport. 1999. Newborns develop a Th1-type response to Mycobacterium
bovis Bacillus-Calmette-Guerin vaccination. J. Immunol. 163:2249–2255.
29. Marodi, L. 2002. Down-regulation of Th1 responses in human neonates.
Clin. Exp. Immunol. 128:1–2.
30. Mascart, F., M. Hainaut, A. Peltier, V. Verscheure, J. Levy, and C. Locht.
2007. Modulation of the infant immune responses by the first pertussis
vaccine administrations. Vaccine 25:391–398.
31. Menozzi, F. D., R. Mutombo, G. Renauld, C. Gantiez, J. H. Hannah, E.
Leininger, M. J. Brennan, and C. Locht. 1994. Heparin-inhibitable lectin
activity of the filamentous hemagglutinin adhesin of Bordetella pertussis.
Infect. Immun. 62:769–778.
32. Mielcarek, N., A.-S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. B. Younes,
C. Creusy, J. Engle, W. E. Goldman, and C. Locht. 2006. Live attenuated B.
pertussis as a single-dose nasal vaccine against whooping cough. PLoS
Pathog. 2:e65.
33. Mielcarek, N., A.-S. Debrie, D. Raze, J. Quatannens, J. Engle, W. E. Gold-
man, and C. Locht. 2006. Attenuated Bordetella pertussis: new live vaccines
for intranasal immunisation. Vaccine 24:S54–S55.
34. Mills, K. H., A. Barnard, J. Watkins, and K. Redhead. 1993. Cell-mediated
immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a
murine respiratory infection model. Infect. Immun. 61:399–410.
35. Mills, K. H. G., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model
in which protection correlates with pertussis vaccine efficacy in children
reveals complementary roles for humoral and cell-mediated immunity in
protection against Bordetella pertussis. Infect. Immun. 66:594–602.
36. Muller, U., S. Reis, J. Hemmi, R. Pavloviv, R. Zinkernagel, and M. Aguet.
1994. Functional role of type I and type II interferons in antiviral defense.
Science 262:1918–1921.
37. Prescott, S. L., C. Macaubas, B. J. Holt, T. B. Smallacombe, R. Loh, and
P. D. Sly. 1998. Transplacental priming of the human immune system to
environmental allergens: universal skewing of initial T cell responses toward
Th2 cytokine profile. J. Immunol. 160:4730–4737.
38. Salmaso, S., P. Mastrantonio, S. G. F. Wassilak, M. Giuliano, A. Anemona,
A. Giammanco, A. E. Tozzi, M. L. Ciofi degli Atti, and D. Greco. 1998.
Persistence of protection through 33 months of age provided by immuniza-
tion in infancy with two three-component acellular pertussis vaccines. Vac-
cine 16:1270–1275.
39. Snapper, C. M., F. D. Finkelman, and W. E. Paul. 1988. Regulation of IgG1
and IgE production by interleukin 4. Immunol. Rev. 102:51–75.
40. Trøseid, M., T. Ø. Jonassen, and M. Steinbakk. 2006. Isolation of Bordetella
pertussis in blood culture from a patient with multiple myeloma. J. Infect.
52:e11–e13.
41. von Ko¨nig, C. H., S. Halperin, M. Riffelmann, and N. Guiso. 2002. Pertussis
of adults and infants. Lancet Infect. Dis. 2:744–750.
42. Weiss, A. A., and M. S. Goodwin. 1989. Lethal infection by Bordetella per-
tussis mutants in the infant mouse model. Infect. Immun. 57:3757–3764.
43. Wolfe, D. N., E. M. Goebel, O. N. Bjornstad, O. Restif, and E. T. Harvill.
2007. The O antigen enables Bordetella parapertussis to avoid Bordetella
pertussis-induced immunity. Infect. Immun. 75:4972–4979.
44. Wolfe, D. N., P. B. Mann, A. M. Buboltz, and E. T. Harvill. 2007. Delayed
role of tumor necrosis factor-alpha in overcoming the effects of pertussis
toxin. J. Infect. Dis. 196:1228–1236.
45. Zachariadis, O., J. Cassidy, C. Brady, and B. P. Mahon. 2006.  T cells
regulate the early inflammatory response to Bordetella pertussis infection in
the murine respiratory tract. Infect. Immun. 74:1837–1845.
VOL. 16, 2009 SAFETY OF A LIVE ATTENUATED B. PERTUSSIS VACCINE 1351
